367909-45-3 Usage
General Description
The chemical compound Benzenebutanoicacid,a-[[(3S)-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]amino]-,ethylester,(aS)- is a complex organic molecule. It consists of a benzene ring attached to a butanoic acid group and an ethyl ester. Additionally, it contains an amino group linked to a tetrahydro-2-oxo-1H-1-benzazepin-3-yl moiety. The stereochemistry of the compound is designated as (aS), indicating a specific configuration around the chiral center. Benzenebutanoicacid,a-[[(3S)-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepin-3-yl]amino]-,ethylester,(aS)- may have potential applications in medicinal chemistry or pharmaceutical research due to its unique structure and diverse functional groups.
Check Digit Verification of cas no
The CAS Registry Mumber 367909-45-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,7,9,0 and 9 respectively; the second part has 2 digits, 4 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 367909-45:
(8*3)+(7*6)+(6*7)+(5*9)+(4*0)+(3*9)+(2*4)+(1*5)=193
193 % 10 = 3
So 367909-45-3 is a valid CAS Registry Number.
367909-45-3Relevant articles and documents
Formal synthesis of the ACE inhibitor benazepril·HCl via an asymmetric aza-Michael reaction
Yu, Luo-Ting,Huang, Ji-Ling,Chang, Ching-Yao,Yang, Teng-Kuei
, p. 641 - 648 (2007/10/03)
A formal enantioselective synthesis of benazepril·HCl (4), an antihypertensive drug, is reported. Our synthesis employed an asymmetric aza-Michael addition of L-homophenylalanine ethyl ester (LHPE, 1) to 4-(2-nitrophenyl)-4-oxo-but-2-enoic acid methyl est
Asymmetric synthesis of ACE inhibitor-Benazepril HCl via a bioreductive reaction
Chang, Ching-Yao,Yang, Teng-Kuei
, p. 2239 - 2245 (2007/10/03)
An enantioselective synthesis of the potent angiotensin converting enzyme (ACE) inhibitor (2S, 3′S)-2-(1-carboxymethyl-2-oxo-2,3,4,5-tetrahydro-1H- benzo[b]azepin-3-ylamino)-4-phenylbutyric acid ethyl ester hydrochloride, Benazepril HCl 4, has been achieved through an asymmetric reduction of 4-(2-nitrophenyl)-2,4-dioxobutyric acid ethyl ester 6b employing baker's yeast as the reductive catalyst.